Scott J. Diede

Scott J. Diede

Auto-generated profile, based on publicly available information

Scott J. Diede

Merck & Co, Inc, Rahway, NJ

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in Cell
Verified
Journal Article
Closed access
ARAntoni Ribas
Antoni Ribas
RDReinhard Dummer
Reinhard Dummer
IPIgor Puzanov
Igor Puzanov
AVAri VanderWalde
Ari VanderWalde
RARobert H.I. Andtbacka
Robert H.I. Andtbacka
GLGeorgina Venetia Long
Georgina Venetia Long

1 August 2019 in The Lancet Oncology
Verified
Journal Article
Closed access
GLGeorgina Venetia Long
Georgina Venetia Long
RDReinhard Dummer
Reinhard Dummer
OHOmid Hamid
Omid Hamid
TGThomas F Gajewski
Thomas F Gajewski
CCChristian Caglevic
Christian Caglevic
TMTara C Mitchell
Tara C Mitchell

10 June 2018 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
Caroline RobertCaroline Robert
Caroline Robert
ARAntoni Ribas
Antoni Ribas
OHOmid Hamid
Omid Hamid
ADAdil Daud
Adil Daud
JWJedd D. Wolchok
Jedd D. Wolchok
FHF. Stephen Hodi
F. Stephen Hodi
Purpose: Pembrolizumab provides durable antitumor activity in metastatic melanoma, including complete response (CR) in about 15% of patients. Data are limited on potential predictors of CR and patient disposition after pembrolizumab discontinuation after CR. We describe baseline characteristics and long-term follow-up in patients who experienced CR with pembrolizumab in the KEYNOTE-001 study ( ClinicalTrials.gov identifier: NCT01295827). Patients and Methods: Patients with ipilimumab-naive or -treated advanced/metastatic melanoma received one of three dose regimens of pembrolizumab. Eligible patients who received pembrolizumab for ≥ 6 months and at least two treatments beyond confirmed CR could discontinue therapy. Response was assessed every 12 weeks by central Response Evaluation Criteria in Solid Tumors version 1.1. For this analysis, CR was defined per investigator assessment, immune-related response criteria, and potential predictors of CR were evaluated using univariate and multivariate analyses. Results: Of 655 treated patients, 105 (16.0%) achieved CR after median follow-up of 43 months. At data cutoff, 92 patients (87.6%) had CR, with median follow-up of 30 months from first CR. Fourteen (13.3%) patients continued to receive treatment for a median of ≥ 40 months. Pembrolizumab was discontinued by 91 patients (86.7%), including 67 (63.8%) who proceeded to observation without additional anticancer therapy. The 24-month disease-free survival rate from time of CR was 90.9% in all 105 patients with CR and 89.9% in the 67 patients who discontinued pembrolizumab after CR for observation. Tumor size and programmed death-ligand 1 status were among the baseline factors independently associated with CR by univariate analysis. Conclusion: Patients with metastatic melanoma can have durable complete remission after discontinuation of pembrolizumab, and the low incidence of relapse after median follow-up of approximately 2 years from discontinuation provides hope for a cure for some patients. The mechanisms underlying durable CR require further investigation.

1 December 1999 in Cell
Verified
Journal Article
Closed access
SDScott J Diede
Scott J Diede
DGDaniel E Gottschling
Daniel E Gottschling

1 January 2020 in The Lancet Oncology
Verified
Journal Article
Closed access
BGBirgit Geoerger
Birgit Geoerger
HKHyoung Jin Kang
Hyoung Jin Kang
MYMichal Yalon-Oren
Michal Yalon-Oren
LMLynley V Marshall
Lynley V Marshall
CVCatherine Vezina
Catherine Vezina
NPNavin Pinto
Navin Pinto

20 January 2023 in Journal of Clinical Oncology
Verified
Journal Article
Open access
JCJason Chesney
Jason Chesney
ARAntoni Ribas
Antoni Ribas
GLGeorgina Venetia Long
Georgina Venetia Long
John M. KirkwoodJohn M. Kirkwood
John M. Kirkwood
Reinhard DummerReinhard Dummer
Reinhard Dummer
HGHelen Gogas
Helen Gogas
PURPOSE: The combination of talimogene laherparepvec (T-VEC) and pembrolizumab previously demonstrated an acceptable safety profile and an encouraging complete response rate (CRR) in patients with advanced melanoma in a phase Ib study. We report the efficacy and safety from a phase III, randomized, double-blind, multicenter, international study of T-VEC plus pembrolizumab (T-VEC-pembrolizumab) versus placebo plus pembrolizumab (placebo-pembrolizumab) in patients with advanced melanoma. METHODS: Patients with stage IIIB-IVM1c unresectable melanoma, naïve to antiprogrammed cell death protein-1, were randomly assigned 1:1 to T-VEC-pembrolizumab or placebo-pembrolizumab. T-VEC was administered at ≤ 4 × 106 plaque-forming unit (PFU) followed by ≤ 4 × 108 PFU 3 weeks later and once every 2 weeks until dose 5 and once every 3 weeks thereafter. Pembrolizumab was administered intravenously 200 mg once every 3 weeks. The dual primary end points were progression-free survival (PFS) per modified RECIST 1.1 by blinded independent central review and overall survival (OS). Secondary end points included objective response rate per mRECIST, CRR, and safety. Here, we report the primary analysis for PFS, the second preplanned interim analysis for OS, and the final analysis. RESULTS: Overall, 692 patients were randomly assigned (346 T-VEC-pembrolizumab and 346 placebo-pembrolizumab). T-VEC-pembrolizumab did not significantly improve PFS (hazard ratio, 0.86; 95% CI, 0.71 to 1.04; P = .13) or OS (hazard ratio, 0.96; 95% CI, 0.76 to 1.22; P = .74) compared with placebo-pembrolizumab. The objective response rate was 48.6% for T-VEC-pembrolizumab (CRR 17.9%) and 41.3% for placebo-pembrolizumab (CRR 11.6%); the durable response rate was 42.2% and 34.1% for the arms, respectively. Grade ≥ 3 treatment-related adverse events occurred in 20.7% of patients in the T-VEC-pembrolizumab arm and in 19.5% of patients in the placebo-pembrolizumab arm. CONCLUSION: T-VEC-pembrolizumab did not significantly improve PFS or OS compared with placebo-pembrolizumab. Safety results of the T-VEC-pembrolizumab combination were consistent with the safety profiles of each agent alone.